Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02350673 · ClinicalTrials.gov registry record · Phase 1
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 14
- Study locations
NCT02350673: Completed Phase 1 study of Solid Tumors, sponsored by Hoffmann-La Roche.
NCT02350673 is a Phase 1 study of Solid Tumors that has completed, run by Hoffmann-La Roche. The registered enrollment target is 70 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (75% lower). The trial reports 14 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02350673, a Phase 1 study of Solid Tumors, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is an open-label, multi-center, Phase Ib clinical study of cergutuzumab amunaleukin, in combination with atezolizumab, to investigate the safety, pharmacokinetics, and therapeutic activity in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors, whose disease has progressed on or who are intolerant to the standard of care therapy. Enrolled participants who continue treatment will be treated until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent. The study will include 2 parts: a dose-escalation Part I and a dose expansion Part II. The anticipated treatment period is 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest a benefit.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Cergutuzumab Amunaleukin
Study Locations (14)
Other
- Herlev Hospital; Onkologisk afdeling - Herlev
- Rigshospitalet; Onkologisk Klinik - København Ø
- Antoni van Leeuwenhoek Ziekenhuis - Amsterdam
- Erasmus MC - Rotterdam
- Hospital Univ Vall d'Hebron; Servicio de Oncologia - Barcelona
- START Madrid. Centro Integral Oncologico Clara Campal; CIOCC - Madrid
- Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia - Valencia
- CHUV; Departement d'Oncologie - Lausanne
New York
- Columbia Univ Med Ctr - New York
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- Yale Cancer Center; Medical Oncology - New Haven
Tennessee
- SCRI-Tennessee Oncology - Nashville
Ontario
- University Health Network; Princess Margaret Hospital; Medical Oncology Dept - Toronto
Navarre
- Clinica Universitaria de Navarra; Servicio de oncología - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-06-29 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
What the finished NCT02350673 record still lists
NCT02350673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02350673 lists 14 locations in 6 states (Other, New York, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02350673 about?
NCT02350673 is a clinical study titled "A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors". This is an open-label, multi-center, Phase Ib clinical study of cergutuzumab amunaleukin, in combination with atezolizumab, to investigate the safety, pharmacokinetics, and therapeutic activity in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumo...
What is the current status of trial NCT02350673?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-06-29. Estimated completion is 2019-12-16.
What conditions does trial NCT02350673 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT02350673?
The interventions under investigation include: Atezolizumab (DRUG), Cergutuzumab Amunaleukin (DRUG).
Who is sponsoring clinical trial NCT02350673?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02350673 being conducted?
This trial has 14 study locations across Connecticut, New York, Tennessee, Ontario, Navarre. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02350673's enrollment target sits among peer trials
70 62nd of 125 higher than 63 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI